TORONTO, Oct. 9 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on treatments and diagnostics for brain-wasting diseases, today
announced that it will be presenting the results from its vaccine development
program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou
Gehrig's disease, at the 132nd Annual Meeting of the American Neurological
Association today in Washington, DC. The vaccine approach, also known as
active immunization, is the second therapeutic approach for which
proof-of-concept has been established by Amorfix for the treatment of ALS this
year. In March, Amorfix established a passive immunization approach in the
same mouse model of ALS by injecting monoclonal antibodies that target the
misfolded superoxide dismutase 1 (SOD1) protein.
